SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV

Hepatology International

Volumn 7, Issue 2, 2013, Pages 683-692

  Hamaoka, Kazuhiro ^a,b   Nagoshi, Sumiko ^a,b   Sugawara, Kayoko ^a,b   Naiki, Kayoko ^a,b   Uchida, Yoshihito ^a,b   Inao, Mie ^a,b   Nakayama, Nobuaki ^a,b   Fujiwara, Kenji ^a,b   Mochida, Satoshi ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Osteopontin; Sex difference; SNPs; SRY

Indexed keywords

CYSTEINE; GLYCINE; HOST FACTOR; OLIGONUCLEOTIDE; OSTEOPONTIN; THREONINE;

ADULT; AGED; ALLELE; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CELL STRAIN HEPG2; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; HAPLOTYPE; HEPATITIS C; HOMOZYGOTE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OSTEOPONTIN GENE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TUMOR GENE;

EID: 84879844980     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9404-1     Document Type: Article

References (43)

1. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-864
2. Kawashima R, Mochida S, Matsui A, et al. Expression of osteopontin in Kupffer cells and hepatic macrophages and stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 1999;256:527-531
3. Wang Y, Mochida S, Kawashima R, et al. Increased expression of osteopontin in activated Kupffer cells and hepatic macrophages during macrophage migration in Propionibacterium acnes-treated rat liver. J Gastroenterol 2000;35:696-701
4. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol 1998;29:1250-1254
5. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Canc Res 1999;5:2271-2277
6. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Canc Epidemiol Biomarkers Prev 2004;13:487-491
7. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-132
8. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 21: 515-523
9. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423
10. Pan HW, Ou YH, Peng SY. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003;98:119-127
11. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002;52:19-24
12. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Canc Metastasis Rev 2008;27:103-118
13. El-Tanani MK, Campbell FC, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463-474
14. Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834-1842
15. Zhao J, Dong L, Lu B, et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008;135:956-968
16. Mochida S, Hashimoto M, Matsui A, et al. Genetic polymorphysms in promoter region of osteopontin gene as a marker for predicting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 2004;313:1079-1085
17. Chiu YW, Tu HF, Wang IK, et al. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol 2010;46:302-306
18. D'Alfonso S, Barizzone N, Giordano M, et al. Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2005;52:539-547
19. Hendig D, Arndt M, Szliska C, Kleesiek K, Götting C. SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. Clin Chem 2007;53:829-836
20. Chen J, Wu Q, Lu Y, et al. SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet 2010;55:456-461
21. Hummelshoj T, Ryder LP, Madsen HO, Odum N, Svejgaard A. A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol 2006;43:980-986
22. Giacopelli F, Marciano R, Pistorio A, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genom 2004;20:87-96
23. Schultz J, Lorenz P, Ibrahim SM, et al. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 2009;48:14-23
24. Nagoshi S. Sex- or gender-specific medicine in Hepatology. Hepatol Res 2008;38:219-224
25. Rodriguez-Torres M, Rios-Bedoya CF, Rodriguez-Orengo J, et al. Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender. J Clin Gastroenterol 2006;40:358-366
26. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574-679
27. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257-265
28. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-739
29. Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:267-272
30. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35(5 Suppl 2):S72-S78
31. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0. Lyon: IARC Press; 2004
32. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996;31:552-558
33. Ng IO, Ng MM, Lai EC, Fan ST. Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer 1995;75:18-22
34. Ng IO, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol 1997;92:1355-1358
35. Fukuda S, Itamoto T, Amano H, et al. Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg 2007;31:345-352
36. Sinclair A, Berta P, Palmer M, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990;346:240-244
37. Naito M, Matsui A, Inao M, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005;40:381-388
38. Ono E, Shiratori Y, Okudaira T, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999;15:192-200
39. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-655
40. Kim J, Ki SS, Lee SD, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006;101:2051-2059
41. Diaz-Hernandez V, Leon del Rio A, Zamora M, Merchant-Larios H. Expression profiles of SRY and SOX9 in rabbit gonads: the classical model of mammalian sex differentiation. Sex Dev 2008;2:152-166
42. Salas-Cortés L, Jaubert F, Bono M, Fellous M, Rosemblatt M. Expression of the human SRY protein during development in normal male gonadal and sex-reversed tissues. J Exp Zool 2001;290:607-615
43. Montazer-Torbati F, Kocer A, Auquste A, et al. A study of goat SRY protein expression suggests putative new roles for this gene in the developing testis of a species with long-lasting SRY expression. Dev Dynam 2010;239:3324-3335